RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to small businesses. Applications closed on February 1, 2023.
From the official notice on Grants.gov, last changed March 30, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under RFA-HG-21-008 were run by National Human Genome Research Institute (NHGRI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HG-21-008 in the NIH Guide.
Key dates
| Posted | March 30, 2021 |
|---|---|
| Deadline | February 1, 2023 |
| Archived by Grants.gov | March 9, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R43/R44 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development: The purpose of the RFA is to refocus and emphasize NHGRIs investment in nucleic acid sequencing technology on novel technology innovation and early development. This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects. The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021.
Funded under RFA-HG-21-008 so far
NIH funded 4 projects under RFA-HG-21-008 in fiscal 2022 to 2024, at 1 institution. The median yearly award was $400,000.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Re-Reading RNA to Obtain High Accuracy | Electronic Biosciences, Inc. | 2024 | $347,026 |
| Sequencing the Mono-Methylated Derivatives of Cytidine | Electronic Biosciences, Inc. | 2023 | $400,000 |
| Nanoscale Tools for Inosine Sequencing | Electronic Biosciences, Inc. | 2023 | $1.0 million |
| Two readers for RNA | Electronic Biosciences, Inc. | 2022 | $393,972 |
Who has won Human Genome Research grants before
From fiscal 2021 to 2025, Human Genome Research (93.172) awarded $2.2 billion across 1,255 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 59 | $153 million |
| University of Washington | Washington | 46 | $123 million |
| The Broad Institute, Inc | Massachusetts | 22 | $119 million |
| University of California Santa Cruz | California | 17 | $64.7 million |
| Baylor College of Medicine | Texas | 24 | $62.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HG-21-008 still open?
No. It closed on February 1, 2023.
Who can apply for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)?
Closed February 1, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-HG-21-008?
NIH RePORTER lists 4 projects funded under RFA-HG-21-008 in fiscal 2022 to 2024, at 1 institution.
Who has won Human Genome Research grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, University of Washington, The Broad Institute, Inc. The program made 1,255 awards worth $2.2 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)